Navigation Links
Verinata Health Announces New Findings At The American Society Of Human Genetics
Date:11/9/2012

REDWOOD CITY, Calif., Nov. 9, 2012 /PRNewswire/ -- Verinata Health, Inc., a privately-held company dedicated to maternal and fetal health, today announced two poster presentations at the 62nd Annual Meeting of the American Society of Human Genetics (ASHG). The conference is being held in San Francisco, California.

(Logo: http://photos.prnewswire.com/prnh/20120425/SF94380LOGO)

"The verifi® prenatal test offers pregnant women access to a blood test that is safe, early and accurate," said Dr. Jeffrey Bird, Executive Chairman and CEO of Verinata Health.  "Looking beyond our current product offering, our early work presented at ASHG represents an exciting possibility for future non-invasive prenatal tests. While this initial work serves as a proof of principal, it clearly demonstrates the power and potential of massively parallel sequencing to detect alterations within individual chromosomes, similar to chromosomal microarrays."

The following posters were presented at ASHG on Thursday, November 8, 2012:

  • Detection of Fetal Sub-Chromosomal Alterations in Maternal Plasma Cell-Free DNA (cfDNA) Using Massively Parallel Sequencing (MPS). (Poster #3021T) This poster demonstrates that Verinata's proprietary technology, together with next-generation sequencing, can be used to detect subchromosomal changes in the fetus.
  • cfDNA is not Compromised by Temperature Stress of Maternal Blood Collected in Streck Cell-Free DNA BCT. (Poster #3007T)

About the verifi® prenatal test
The verifi® prenatal test is a blood test that analyzes genetic material (or DNA) naturally found in a pregnant woman's blood to detect the most common fetal chromosome abnormalities.  When directed by a physician, the verifi test can be offered to pregnant women of at least 10 weeks gestation at high risk of carrying a fetus with a genetic abnormality. A physician may classify a woman as "high-risk" if she is over 35 years of age, has a prior personal or family history of chromosome abnormalities, or has had a positive initial screening test indicating she is at increased risk for carrying a fetus with a genetic abnormality.

Verinata Health, Inc.
Verinata is driven by a sole, extraordinary purpose – maternal and fetal health. Our initial focus is to develop and offer non-invasive tests for early identification of fetal chromosomal abnormalities using our proprietary technologies. We aim to reduce the anxiety associated with today's multi-step process, the unacceptable false-positive rates, the non-specific and sometimes confusing results of current prenatal screening methods, as well as the risk of current invasive procedures. In support of national guidelines recommending first trimester aneuploidy risk assessment, we believe women who desire such an assessment should be offered a single blood draw test with a definitive result. The verifi® prenatal test is available throughout the United States, with the exception of New York, through a physician. For more information about Verinata, please go to www.verinata.com.


'/>"/>
SOURCE Verinata Health, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Genomic Health to Present at Two Upcoming Investor Conferences
2. Baylor University scientist receives major grants for health research on 1991 Gulf War veterans
3. Obese dogs at risk of health condition experienced by humans
4. Obese moms give birth to heart healthier kids following bariatric surgery
5. New Study Shows That Improvements in Employee Health Behaviors Persist Over Two Years
6. US investment in biomedical and health research on downward trend
7. Omega-3 intake heightens working memory in healthy young adults
8. Pigs look healthy but test positive for flu at fairs; transmission seen between pigs and humans
9. INTEGRIS Health Puts Patient Safety in the Palm of Your Hand
10. Study: DNA barcoding can ID natural health products
11. App lets you monitor lung health using only a smartphone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... Solutions, a global clinical research organization (CRO), announces the launch of ... 4, 2017. Shadow is designed to assist medical writers and biometrics ... the European Medicines Agency (EMA) in meeting the requirements for de-identifying ... ... ...
(Date:8/15/2017)... --  ivWatch LLC , a medical device company focused on improving ... of its ISO 13485 Certification, the global standard for medical device ... (ISO®). ... Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as it ...
(Date:6/30/2017)... ARLINGTON, Va. , June 30, 2017 /PRNewswire-USNewswire/ ... a leading developer and supplier of face and ... the ATA Featured Product provider program. ... created an innovative way to monitor a driver,s ... benefit greatly from being able to detect fatigue ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... ... 10, 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, ... The bold new look is part of a transformation to increase awareness, appeal ... growth period. , It will also expand its service offering from its signature gourmet ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the ... won a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to ... Experience from US2020. , US2020’s mission is to change the trajectory of STEM ...
(Date:10/10/2017)... , Oct. 10, 2017 International research firm Parks ... Strategy, will speak at the TMA 2017 Annual Meeting , October ... trends in the residential home security market and how smart safety and ... Parks ... "The residential ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... process optimization firm for the life sciences and healthcare industries, announces a presentation ... San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will ...
Breaking Biology Technology: